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Background: Coexisting of Graves’ disease and functioning struma ovarii is a rare condition. Although the histology
of struma ovarii predominantly composed of thyrocytes, the majority of the patients did not have thyrotoxicosis.
The mechanism underlying the functioning status of the tumor is still unclear but the presence of thyroid
stimulating hormone receptor (TSHR) is thought to play a role. Here we describe the patient presentation and
report the TSHR expression of the tumor.
Case presentation: A 56-year old Asian woman presented with long standing thyrotoxicosis for 23 years. She was
diagnosed with Graves’ disease and thyroid nodules. She had bilateral exophthalmos and had high titer of plasma
TSHR antibody. Total thyroidectomy was performed and the histologic findings confirmed the clinical diagnosis.
The patient had persistent thyrotoxicosis postoperatively. Thyroid uptake demonstrated the adequacy of the thyroid
surgery and the whole body scan confirmed the presence of functioning thyroid tissue at pelvic area. The surgery
was scheduled and the patient had hypothyroidism after the surgery. The pathological diagnosis was struma ovarii
at right ovary. We performed TSHR staining in both the patient’s struma ovarii and in 3 cases of non-functioning
struma ovarii. The staining results were all positive and the intensity of the TSHR staining of functioning struma ovarii
was the same as that in other cases of non-functioning tumors, suggesting that the determinant of functioning struma
ovarii might be the presence of TSHR stimuli rather than the intensity of the TSHR in the ovarian tissue.
Conclusion: In patients with Graves’ disease with persistent or recurrent thyrotoxicosis after adequate ablative
treatment, the possibility of ectopic thyroid hormone production should be considered. TSHR expression is found in
patients with functioning and non-functioning struma ovarii and cannot solely be used to determine the functioning
status of the tumor.
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Coexisting of Graves’ disease and functioning struma
ovarii is a rare condition. Struma ovarii is a rare ovarian
tumor. Most affected patients are asymptomatic; however
thyrotoxicosis from struma ovarii has been reported in
5 % to 15 % of the confirmed cases [1, 2]. Although the
histology of struma ovarii predominantly composed of
thyrocytes, the majority of the patients do not have thyro-
toxicosis. The mechanism underlying the functioning sta-
tus of the tumor is still unclear. The expression of* Correspondence: nuntakorn@hotmail.com
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to play a role [3, 4]. The diagnosis of functioning struma
ovarii is challenging especially when the patient had func-
tioning thyroid gland. Here we report an usual case of
coexisting Graves’ disease with functioning struma ovarii
and the TSHR staining result, including the TSHR staining
of the patient with non-functioning struma ovarii.
Case presentation
A 56-year-old woman presented with persistent thyrotoxi-
cosis. She was first diagnosed with thyrotoxicosis 23 years
previously and had been periodically treated with antithy-
roid drugs for several years at a time. On examination, she
had bilateral exophthalmos. Her thyroid gland was enlargedicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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antibody level was elevated at 3.86 IU/L (reference
range, <1.00 IU/L), thus confirming the diagnosis of
Graves’ disease with thyroid nodules.
A thyroid scan with Tc99m showed generalized in-
creased uptake in the thyroid gland with visualized activ-
ity in the pyramidal lobe. One hyperfunctioning nodule
at the upper pole of the right lobe and another hypo-
functioning nodule in the middle aspect of the right lobe
were demonstrated (Fig. 1). The provisional diagnosis at
that time was Graves’ disease with thyroid nodules, and
ablative treatment was planned. Ultrasound-guided fine-
needle aspiration yielded an area of undetermined sig-
nificance. Total thyroidectomy was performed without
perioperative complications. The surgical specimen con-
tained 57.7 g of thyroid tissue. The histological findings
supported the clinical diagnosis of Graves’ disease and
benign thyroid nodules.
Two weeks after total thyroidectomy, the patient’s
symptoms of thyrotoxicosis recurred. The differential
diagnosis included inadequate thyroidectomy or a source
of extrathyroidal thyrotoxicosis such as functioning
struma ovarii. A thyroid function test confirmed the
presence of post-thyroidectomy thyrotoxicosis (Table 1).
The radioactive iodine uptake was evaluated to check
the adequacy of the thyroid surgery, and very low uptake
of 0.2 % was found in the thyroid bed (reference range,
15 %–45 %). A radioactive iodine (I131) whole-body scan
demonstrated intense radiotracer uptake with a star
artifact in the pelvic region. Single-photon emission
computed tomography/computed tomography of theFig. 1 Tc99m thyroid scan showed diffusely increased uptake by the
thyroid tissue with thyroid nodulespelvis confirmed the presence of inhomogeneous in-
creased radiotracer uptake by an 8.5- × 7.2-cm mixed
multicystic-solid mass with internal calcification in the
right adnexal region (Fig. 2). The plasma level of cancer
antigen 125 was elevated at 48.55 U/ml (reference range,
0–35 U/ml). Therefore the patient was diagnosed with
coexisting Graves’ disease and functioning struma ovarii
and surgery is scheduled. Preoperative control of thyro-
toxicosis is required to prevent thyroid storm during the
surgery. In the present case, therefore, the patient’s methi-
mazole was restarted, and a euthyroid state was achieved
before scheduling total abdominal hysterectomy with bi-
lateral salpingo-oophorectomy (TAH with BSO).
The patient’s perioperative course was uneventful. An
8.0- × 5.5- × 5.0-cm right ovarian mass with minimal as-
cites was found, the cut surfaces of the ovary showed
solid-cystic appearance. The solid component showed
soft red-brown and yellowish semitranslucent tissue re-
sembling thyroid tissue. The cystic spaces contained
clear yellow fluid.
The histological diagnosis was struma ovarii of the right
ovary, without evidence of malignancy. Immunohisto-
chemical staining for thyroglobulin (clone 2H11 + 6E1;
Cell Marque) was positive; this result confirmed the thy-
roid epithelial nature of the lesion (Fig. 3b). Moreover, im-
munohistochemical staining for TSHR (clone 4C1/E1/G8;
Abcam) was performed with normal thyroid tissue as a
positive control and normal ovarian tissue as a negative
control. Immunohistochemical staining was performed by
autostainer (Ventana Benchmark XT). The result showed
that the struma ovarii tissue in our patient was positive for
TSHR, indicating the presence of TSHR expression in the
struma ovarii tissue (Fig. 3c). Two weeks postoperatively,
the patient’s thyroid hormone levels were in the
hypothyroid range. Replacement therapy with levothyrox-
ine was initiated, and euthyroidism was achieved.
Discussion
Struma ovarii is a rare ovarian germ cell tumor which is
entirely or predominantly composed of thyroid tissue [5].
Struma ovarii has been reported in 0.3 % to 1.0 % of all
ovarian tumors and 2.0 % to 4.0 % of all ovarian teratomas
[1]. It commonly occurs in the fourth to sixth decades of
life, and it is usually benign and unilateral. Most affected
patients are asymptomatic. However, patients may seek
medical attention because of compressive symptoms in-
volving a nearby organ, ascites, or even thyrotoxicosis.
Thyrotoxicosis from struma ovarii has been reported in
5 % to 15 % of the confirmed cases [1–3, 6], but it is noted
to be rare for tumors of <3 cm [7]. However, the
actual incidence remains unclear owing to a lack of pre-
cise data on thyroid function in affected patients. Thyro-
toxicosis in patients with struma ovarii has three potential
causes: a hyperfunctioning struma ovarii alone, both a
Table 1 Thyroid hormone levels and management at baseline and during follow-up
At first presentation Before total
thyroidectomy




2 weeks after TAH
with BSO
Free T4 (0.93–1.70 ng/dl) – 1.14 4.8 1.43 0.11
Total T4 (4.50–11.70 μg/dl) 17.27 – – – –
Total T3 (80–200 ng/dl) 233 167.5 380.7 153.2 –
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hyperfunctioning thyroid gland with an incidental non-
functioning struma ovarii [7]. The diagnosis of a function-
ing struma ovarii is challenging, especially in a patient
with a hyperfunctioning thyroid gland. The evidence for
the presence of a hyperfunctioning struma ovarii is based
on increased radioiodine uptake by the ovary on an I131
whole-body scan [6]. Cervical goiter is quite common in
patients with struma ovarii (16 %–40 %) [1, 2]. Because
Graves’ disease is the most common cause of hyperthy-
roidism with diffuse thyroid gland enlargement, a number
of previous cases of thyrotoxicosis due to struma ovarii
were incorrectly treated by thyroidectomy [6, 7]. The co-
existence of Graves’ disease and a hyperfunctioning
struma ovarii is extremely rare. The characteristic of the
prior case reports were summarized in Table 2. In most
cases, the diagnosis was based on persistent postoperative
thyrotoxicosis. In only two cases were both coexisting
diseases simultaneously diagnosed [1, 8]. The optimalFig. 2 I131 whole-body scan after total thyroidectomy revealed a star artifacpreoperative method for diagnosis of hyperfunctioning
struma ovarii is either confirmation of the presence of
thyrotoxicosis despite the absence of hyperfunctioning
thyroid tissue or low radioiodine uptake at the neck
along with high ovarian uptake of radioiodine tracer.
Increased uptake of radioiodine by an ovarian tumor
on a whole-body scan alone is insufficient for diagno-
sis of hyperfunctioning struma ovarii because it report-
edly yields both false-positive and false-negative results
[9–14]. The main differential diagnosis for increased
uptake of radiotracer in the abdomen is ovarian metas-
tasis from primary thyroid cancer.
Similar to most cases, the hyperthyroidism in our pa-
tient was thought to have arisen only from Graves’ disease
based on typical signs of diffuse thyroid gland enlarge-
ment, bilateral exophthalmos, diffuse thyroid uptake with
visualized activity in the pyramidal lobe, and an elevated
level of plasma TSHR antibody. However, persistent post-
thyroidectomy thyrotoxicosis with low I131 uptake at thet lesion in the pelvic area
Fig. 3 a H&E staining of our patient’s ovarian section revealed typical thyroid follicles. b The thyroid tissue in our patient’s ovarian tumor was
highlighted by thyroglobulin antibody. c Immunostaining for TSH receptor showed positive staining in our patient’s struma ovarii. d TSH receptor
also expressed on the tumor cells from other patient with non-functioning struma ovarii
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moval of the struma ovarii confirmed the diagnosis of a
functioning struma ovarii.
The pathophysiology of thyrotoxicosis from struma
ovarii remains unclear. The finding of tall thyroidal epi-
thelium with scattered papillary infoldings, which is fre-
quently found in struma ovarii, has a poor correlation
with the presence of clinical thyrotoxicosis [7]. There
are two proposed mechanisms underlying the patho-
physiology of functioning struma ovarii. First, the ovar-
ian tumor may have autonomous function, as in toxic
multinodular goiter [7]. Second, in patients with coexist-
ing Graves’ disease, TSHR antibodies stimulate the
struma ovarii in the same way that they stimulate the
thyroid tissue to cause Graves’ disease. Our patient’s
ovarian section revealed typical thyroid follicles without
features of malignancy. Immunohistochemical staining
for the TSHR in the struma ovarii tissue was positive
(Fig. 3c), thus supporting the second hypothesis [3, 4].
We performed TSHR staining in the struma ovarii of an-
other patient with normal thyroid function test pre-
operatively and two other patients without confirm
thyroid function test but was clinically euthyroid pre-
operatively. The staining results were all positive and the
intensity of the TSHR staining of functioning strum ovarii
was the same as that in other cases of nonfunctioningstruma ovarii (Fig. 3d), suggesting that the determinant of
functioning struma ovarii might be the presence of TSHR
stimuli rather than the intensity of the TSHR in the
ovarian tissue. In prior case reports of coexisting
Graves’ disease and struma ovarii, the diagnosis of
functioning struma ovarii almost always follows the
diagnosis of Graves’ disease by several years. The cir-
culating TSHR antibody in Graves’ disease presumably
has a stimulatory effect on the thyroid tissue in the
ovary, resulting in gradual growth and increased thy-
roid hormone production [3, 15].
Approximately 5 % of struma ovarii are malignant, re-
gardless of whether they are functional, and tissue sam-
pling for malignancy testing is very difficult. Therefore,
struma ovarii should be surgically removed in all cases.
Meanwhile, the coexisting Graves’ disease can be managed
medically, surgically, or by radioactive iodine ablation.Conclusions
In patients with Graves’ disease with persistent or recur-
rent thyrotoxicosis after adequate ablative treatment, the
possibility of ectopic thyroid hormone production such as
that from struma ovarii or a metastatic differentiated thy-
roid cancer should be considered. TSHR expression is
found in patients with functioning and non-functioning
Table 2 Cases of Coexisting Graves’ disease and Functioning Struma Ovarii
































64 Yes NA NA NA NA NA Yes NA NA NA NA No 18
Lefort,
1981 [9]
38 Yes NA NA No No Positive NA NA Positive Right 7 No 12
Lazarus,
1987 [15]
48 Yes NA NA NA Few Positive Yes 14 years Positive Left 9 No 24
Kung,
1990 [10]
40 No NA No NA No Positive No 23 weeks NA Right 5 No 4
Banyot,
1995 [1]
30 No No Yes NA NA Negative No NA Positive Right 7 NA 0
Grandet,
2000 [16]
78 NA NA NA NA Few NA Yes NA Positive Bilateral 10 No 4
Kano,
2000 [8]
50 NA NA NA NA Yes Positive No NA NA Left 7 Yes 0
Mimura,
2001 [6]
26 No No NA NA NA Positive No NA Positive Left 16 No 4
Sussman,
2002 [17]
53 No NA No NA NA NA No NA NA Right 7.5 Yes 5
Bartel,
2005 [18]
54 NA NA NA NA NA Positive Yes NA Positive Left NA No 23
Guida,
2005 [11]
42 Yes NA NA No Marked NA Yes NA Negative Right 12 No 1
Teale,
2006 [4]
36 Yes NA NA NA NA Positive Yes NA NA Left 13.5 No 8
Chiofalo,
2007 [19]
42 No NA Yes NA Yes Positive Yes NA Positive Right 12 No 0.5
Wong,
2009 [2]
44 Yes Yes Yes NA NA Positive Yes NA NA Left NA Yes 1
Anastasilakis,
2013 [3]
49 No NA NA Yes Moderate Positive No NA NA Right 18 No 2
Our case,
2015
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functioning status of the tumor.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the editor of this journal.
Abbreviations
TSHR: Thyroid-stimulating hormone receptor; I131: Radioactive iodine; TAH with
BSO: Total abdominal hysterectomy with bilateral salpingo-oophorectomy;
NA: Not available.
Completing interests
The authors declare that they have no competing interests.
Authors’ contributions
TS treated the patient, gathered data and drafted the manuscript. SH
prepared, analysed, and interpreted the histopathological samples, and
critically reviewed the manuscript. TP critically reviewed the manuscript.
NT treated the patient, conceptualized the case report, gathered data, and
critically reviewed the manuscript. All authors approved the final version of
the manuscript.
Acknowledgements
Language editing by Edanz.
Author details
1Division of Endocrinology and Metabolism, Faculty of Medicine Siriraj
Hospital, Mahidol University, Bangkok 10700, Thailand. 2Department of
Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
10700, Thailand.
Received: 31 August 2015 Accepted: 20 October 2015
References
1. Bayot MR, Chopra IJ. Coexistence of struma ovarii and Graves’ disease.
Thyroid. 1995;5(6):469–71.
2. Wong LY, Diamond TH. Severe ophthalmopathy developing after treatment
of coexisting malignant struma ovarii and Graves’ disease. Thyroid.
2009;19(10):1125–7. doi:10.1089/thy.2008.0422.
3. Anastasilakis AD, Ruggeri RM, Polyzos SA, Makras P, Molyva D, Campenni A,
et al. Coexistence of Graves’ disease, papillary thyroid carcinoma and
unilateral benign struma ovarii: case report and review of the literature.
Metabolism. 2013;62(10):1350–6. doi:10.1016/j.metabol.2013.05.013.
4. Teale E, Gouldesbrough DR, Peacey SR. Graves’ disease and coexisting
struma ovarii: struma expression of thyrotropin receptors and the presence
of thyrotropin receptor stimulating antibodies. Thyroid. 2006;16(8):791–3.
doi:10.1089/thy.2006.16.791.
5. Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically
malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol
Pathol. 1993;12(4):333–43.
6. Mimura Y, Kishida M, Masuyama H, Suwaki N, Kodama J, Otsuka F, et al.
Coexistence of Graves’ disease and struma ovarii: case report and literature
review. Endocr J. 2001;48(2):255–60.
7. Kempers RD, Dockerty MB, Hoffman DL, Bartholomew LG. Struma ovarii–ascitic,
hyperthyroid, and asymptomatic syndromes. Ann Intern Med. 1970;72(6):883–93.
8. Kano H, Inoue M, Nishino T, Yoshimoto Y, Arima R. Malignant struma ovarii with
Graves’ disease. Gynecol Oncol. 2000;79(3):508–10. doi:10.1006/gyno.2000.5966.
9. Lefort G, Commenges-Ducos M, Denechaud M, Rivel J, Latapie JL. Ovarian
goiter in Basedow’s disease. Role of thyroid-stimulating immunoglobulins?
Nouv Presse Med. 1981;10(26):2209–10.
10. Kung AW, Ma JT, Wang C, Young RT. Hyperthyroidism during pregnancy
due to coexistence of struma ovarii and Graves’ disease. Postgrad Med J.
1990;66(772):132–3.
11. Guida M, Mandato VD, Di Spiezio SA, Di Carlo C, Giordano E, Nappi C.
Coexistence of Graves’ disease and benign struma ovarii in a patient withmarked ascites and elevated CA-125 levels. J Endocrinol Invest.
2005;28(9):827–30.
12. Ghander C, Lussato D, Conte Devolx B, Mundler O, Taieb D. Incidental
diagnosis of struma ovarii after thyroidectomy for thyroid cancer: functional
imaging studies and follow-up. Gynecol Oncol. 2006;102(2):378–80.
doi:10.1016/j.ygyno.2006.01.047.
13. Joja I, Asakawa T, Mitsumori A, Nakagawa T, Akaki S, Yamamoto M, et al.
I-123 uptake in nonfunctional struma ovarii. Clin Nucl Med. 1998;23(1):10–2.
14. Nodine JH, Maldia G. Pseudostruma ovarii. Obstet Gynecol. 1961;17:460–3.
15. Lazarus JH, Richards AR, MacPherson MJ, Dinnen JS, Williams ED, Owen GM,
et al. Struma ovarii: a case report. Clin Endocrinol (Oxf). 1987;27(6):715–20.
16. Grandet PJ, Remi MH. Struma ovarii with hyperthyroidism. Clin Nucl Med.
2000;25(10):763–5.
17. Sussman SK, Kho SA, Cersosimo E, Heimann A. Coexistence of malignant
struma ovarii and Graves’ disease. Endocr Pract. 2002;8(5):378–80.
doi:10.4158/EP.8.5.378.
18. Bartel TB, Juweid ME, O’Dorisio T, Sivitz W, Kirby P. Scintigraphic detection
of benign struma ovarii in a hyperthyroid patient. J Clin Endocrinol Metab.
2005;90(6):3771–2. doi:10.1210/jc.2005-0147.
19. Chiofalo MG, Misso C, Insabato L, Lastoria S, Pezzullo L. Hyperthyroidism
due to coexistence of Graves’ disease and Struma ovarii. Endocr Pract.
2007;13(3):274–6. doi:10.4158/EP.13.3.274.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
